Although no significant modulations in CD4+ regulatory T cells (Treg) were seen in any patient after therapy, we observed a substantial increase in this cell subset early in the treatment of melanoma patients, and mainly in non-responder ones (Figure 5). The gene discussed is CD4; the disease is melanoma.